In this study, we aimed to assess whether use of GLP-1 receptor agonists among patients with type 2 diabetes and stage 5 CKD or ESKD was associated with better outcomes compared with use of DPP-4 inhibitors. Here, DPP4 is linked to type 2 diabetes mellitus.